Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
Mutations in GTPase KRAS, concretely KRAS G12D, are predominant in pancreatic and colorectal cancers and targeting them is still a challenge. Researchers have published results from studies of a new KRAS G12D inhibitor, LPM-5140276, for the potential treatment of these cancer types harboring this mutation.
Med-tech companies with an AI component in their solutions will certainly find investors willing to back them. AI after all, is being used to develop more effective, smarter technologies. However, investors will only deploy capital into innovations that address genuine clinical needs. The aging population is driving interest in devices targeting cardiovascular and musculoskeletal disorders, and other solutions geared toward neurological conditions, women’s health and diagnostics are also attracting investor attention.
Gilead Sciences is stepping deeper into synthetic lethality, licensing a clinic-ready MAT2A (methionine adenosyltransferase 2a) inhibitor from Suzhou, China-based Genhouse Bio Co. Ltd. in a deal worth up to $1.53 billion.
Less than four months after company officials said they would explore options to find ways of maximizing shareholder value, Sensei Biotherapeutics Inc. disclosed the buyout of Faeth Therapeutics Inc. by way of a stock-for-stock deal – news that sent shares (NASDAQ:SNSE) to a closing price Feb. 18 of $26.25, up $17.12, or 187.5%.
A project that started as a bioreactor to assist astronauts in deep space to keep medications safe in a microgravity environment could help pharma companies model how drugs behave in the human body. Omnigeniq unveiled at the J.P. Morgan Healthcare conference the first computer model of a human protein as it exists in the body, confirming that native protein topology can be calculated directly from physics.
Shenzhen Targetrx Inc. has designed new proteolysis targeting chimeric (PROTACs) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR L858R-, L858R/T790M double mutant- and L858R/T790M/C797S triple mutant-targeting moiety through a linker reported to useful for the treatment of non-small-cell lung cancer.
Tyra Biosciences Inc. has disclosed new indazole compounds acting as fibroblast growth factor receptor (FGFR) inhibitors. They are reported to be useful for the treatment of cancer and developmental disorders.
Although physiological immune responses require increased tissue vasculature, many solid tumors simultaneously activate angiogenesis to meet the increasing demand for oxygen and nutrients while excluding immune cells. The exact molecular mechanisms by which cancer cells control this immune-refractory angiogenic process remain widely unclear.
Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane tyrosine kinase that regulates signaling pathways controlling cell survival and proliferation. Dysregulation of FGFR2, through amplification or activating mutations, contributes to tumor development, making it an attractive target for therapeutic intervention in oncology.
RSS
